WebGemcitabine plus cisplatin remains the standard first-line systemic therapy for advanced cholangiocarcinoma and offers a median survival of approximately 1 year. No standard regimens beyond the first line and no targeted or immunotherapy agents are approved yet in this disease. Development of molecu … WebSep 5, 2024 · In the single-arm findings reported at the 2024 ILCA Conference, 24 patients with intrahepatic cholangiocarcinoma were assigned to 1 course of SIRT-Y90 administered via the hepatic artery at a dose of at least 120 Gy to the intrahepatic tumor. Patients then received a maximum 8 cycles of chemotherapy with cisplatin at a dosage of 25 mg/m2 on ...
Immunotherapy in cholangiocarcinoma : Current Opinion in ... - LWW
WebMismatch repair protein deficiency or microsatellite instability–high cancer is a consistently reliable biomarker for PD-1 and PD-L1 blockade immunotherapy. 24 However, MMR deficiency or microsatellite … WebA Study of ABC294640 (Yeliva®) in the Treatment of Patients with Advanced Cholangiocarcinoma Scottsdale/Phoenix, AZ. ABC-108 is a single-arm Phase IIA clinical study of ABC294640 (Yeliva ®) in the treatment of cholangiocarcinoma (CCA). In this clinical study, all participants will be receiving ABC294640. The study drug, ABC294640 … check register program for senior citizens
Cholangiocarcinoma Nature Reviews Disease Primers
WebJan 25, 2024 · Immunotherapy has emerged as a potent strategy for many different types of cancer and has shown efficacy in combination with chemotherapy for cholangiocarcinoma. In this Review, we discuss ... WebSep 12, 2024 · “The genetic mutation known as microsatellite instability (or MSI-H/dMMR) is really sensitive to immunotherapy,” explains Dr. Kamath. “That particular mutation or … WebApr 17, 2024 · Cholangiocarcinoma is a rare form of cancer that forms in bile ducts, which are slender tubes that carry the digestive fluid bile from the liver to gallbladder and small … check register pdf printable